Cargando…

Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review

Intrahepatic cholangiocarcinoma (ICC) is one of the most common invasive malignant tumors, with a 5-year survival rate of less than 5%. Currently, radical surgical resection is the preferred treatment for ICC. However, most patients are only diagnosed at an advanced stage and are therefore not eligi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhongyan, Wang, Xin, Li, Hehe, Sun, Huimin, Chen, Jianhong, Lin, Hongfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475830/
https://www.ncbi.nlm.nih.gov/pubmed/37671157
http://dx.doi.org/10.3389/fimmu.2023.1230261
_version_ 1785100800684457984
author Zhang, Zhongyan
Wang, Xin
Li, Hehe
Sun, Huimin
Chen, Jianhong
Lin, Hongfeng
author_facet Zhang, Zhongyan
Wang, Xin
Li, Hehe
Sun, Huimin
Chen, Jianhong
Lin, Hongfeng
author_sort Zhang, Zhongyan
collection PubMed
description Intrahepatic cholangiocarcinoma (ICC) is one of the most common invasive malignant tumors, with a 5-year survival rate of less than 5%. Currently, radical surgical resection is the preferred treatment for ICC. However, most patients are only diagnosed at an advanced stage and are therefore not eligible for surgery. Herein, we present a case of advanced ICC in which radical surgery was not possible due to tumor invasion of the second porta hepatis and right hepatic artery. Six treatment cycles with a gemcitabine and oxaliplatin (GEMOX) regimen combined with camrelizumab immunotherapy achieved a partial response and successful tumor conversion, as tumor invasion of the second porta hepatis and right hepatic artery was no longer evident. The patient subsequently underwent successful radical surgical resection, including hepatectomy, caudate lobe resection, and cholecystectomy combined with lymph node dissection. Cases of patients with advanced ICC undergoing surgical resection after combined immunotherapy and chemotherapy are rare. The GEMOX regimen combined with camrelizumab demonstrated favorable antitumor efficacy and safety, suggesting that it might be a potential feasible and safe conversion therapy strategy for patients with advanced ICC.
format Online
Article
Text
id pubmed-10475830
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104758302023-09-05 Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review Zhang, Zhongyan Wang, Xin Li, Hehe Sun, Huimin Chen, Jianhong Lin, Hongfeng Front Immunol Immunology Intrahepatic cholangiocarcinoma (ICC) is one of the most common invasive malignant tumors, with a 5-year survival rate of less than 5%. Currently, radical surgical resection is the preferred treatment for ICC. However, most patients are only diagnosed at an advanced stage and are therefore not eligible for surgery. Herein, we present a case of advanced ICC in which radical surgery was not possible due to tumor invasion of the second porta hepatis and right hepatic artery. Six treatment cycles with a gemcitabine and oxaliplatin (GEMOX) regimen combined with camrelizumab immunotherapy achieved a partial response and successful tumor conversion, as tumor invasion of the second porta hepatis and right hepatic artery was no longer evident. The patient subsequently underwent successful radical surgical resection, including hepatectomy, caudate lobe resection, and cholecystectomy combined with lymph node dissection. Cases of patients with advanced ICC undergoing surgical resection after combined immunotherapy and chemotherapy are rare. The GEMOX regimen combined with camrelizumab demonstrated favorable antitumor efficacy and safety, suggesting that it might be a potential feasible and safe conversion therapy strategy for patients with advanced ICC. Frontiers Media S.A. 2023-08-21 /pmc/articles/PMC10475830/ /pubmed/37671157 http://dx.doi.org/10.3389/fimmu.2023.1230261 Text en Copyright © 2023 Zhang, Wang, Li, Sun, Chen and Lin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Zhongyan
Wang, Xin
Li, Hehe
Sun, Huimin
Chen, Jianhong
Lin, Hongfeng
Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review
title Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review
title_full Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review
title_fullStr Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review
title_full_unstemmed Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review
title_short Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review
title_sort case report: camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475830/
https://www.ncbi.nlm.nih.gov/pubmed/37671157
http://dx.doi.org/10.3389/fimmu.2023.1230261
work_keys_str_mv AT zhangzhongyan casereportcamrelizumabcombinedwithgemcitabineandoxaliplatininthetreatmentofadvancedintrahepaticcholangiocarcinomaacasereportandliteraturereview
AT wangxin casereportcamrelizumabcombinedwithgemcitabineandoxaliplatininthetreatmentofadvancedintrahepaticcholangiocarcinomaacasereportandliteraturereview
AT lihehe casereportcamrelizumabcombinedwithgemcitabineandoxaliplatininthetreatmentofadvancedintrahepaticcholangiocarcinomaacasereportandliteraturereview
AT sunhuimin casereportcamrelizumabcombinedwithgemcitabineandoxaliplatininthetreatmentofadvancedintrahepaticcholangiocarcinomaacasereportandliteraturereview
AT chenjianhong casereportcamrelizumabcombinedwithgemcitabineandoxaliplatininthetreatmentofadvancedintrahepaticcholangiocarcinomaacasereportandliteraturereview
AT linhongfeng casereportcamrelizumabcombinedwithgemcitabineandoxaliplatininthetreatmentofadvancedintrahepaticcholangiocarcinomaacasereportandliteraturereview